Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Repeat Dosing Clinical Trial of SB-509 in Subjects With Moderate to Severe Diabetic Neuropathy and Unmeasurable Nerve Conduction Velocity

NCT00476931 is registered in ClinicalTrials.gov with Sangamo Therapeutics as lead sponsor.

NCT NCT00476931
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00476931 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Repeat Dosing Clinical Trial of SB-509 in Subjects With Moderate to Severe Diabetic Neuropathy and Unmeasurable Nerve Conduction Velocity
Lead sponsor
Sangamo Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2007
Completion date
December 31, 2010
Enrollment
91 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 1, diabetes mellitus, type 2, diabetic polyneuropathy